Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyban goes generic

Executive Summary

Impax/Teva launch first generic version of GlaxoSmithKline's Zyban (bupropion 150 mg) after Andrx relinquishes 180-day marketing exclusivity. Impax' ANDA was approved March 27; under a July 2003 agreement, Andrx will share in the profits of the Impax/Teva product for six months. Andrx also gave up first-to-file rights on the compound for antidepressant use, allowing launch of Wellbutrin SR generics in March (1"The Pink Sheet" March 29, 2004, p. 27)...
Advertisement

Related Content

Wellbutrin SR Generics Multiply As Andrx Relinquishes Exclusivity
Wellbutrin SR Generics Multiply As Andrx Relinquishes Exclusivity
Advertisement
UsernamePublicRestriction

Register

PS044096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel